Real-World Costs of Continuous Insulin Pump Therapy and Multiple Daily Injections for Type 1 Diabetes: A Population-Based and Propensity-Matched Cohort From the Swedish National Diabetes Register
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate real-world costs of continuous insulin pump therapy compared with multiple daily injection (MDI) therapy for type 1 diabetes. RESEARCH DESIGN AND METHODS: Individuals with type 1 diabetes and pump therapy in the Swedish National Diabetes Register (NDR) since 2002 were eligible. Control subjects on MDI were matched 2:1 using time-varying propensity scores. Longitudinal data on health care resource use, antidiabetes treatment, sickness absence, and early retirement were taken from national registers for 2005–2013. Mean annual costs were analyzed using univariate analysis. Regression analyses explored the role of sociodemographic factors. Subgroup and sensitivity analyses were performed. RESULTS: A total of 14,238 individuals with type 1 diabetes entered in the NDR between 2005 and 2013 (insulin pump n = 4,991, MDI n = 9,247, with switches allowed during the study) were included. Mean age at baseline was 34 years, with 21 years of diabetes duration and a mean HbA1c of 8.1% (65 mmol/mol). We had 73,920 person-years of observation with a mean follow-up of 5 years per participant. Mean annual costs were higher for pump therapy than for MDI therapy ($12,928 vs. $9,005, respectively; P < 0.001; mean difference $3,923 [95% CI $3,703–$4,143]). Health care costs, including medications and disposables, accounted for 73% of the costs for pump therapy and 63% of the costs for MDI therapy. Regression analyses showed higher costs for low education, low disposable income, women, and older age. CONCLUSIONS: Nine years of real-world data on all measurable diabetes-related resource use show robust results for additional costs of insulin pump therapy in adults by subgroup and alternative propensity score specifications. Identification of tangible and intangible benefits of pump therapy over time remain important to support resource allocation decisions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mortality and cardiovascular disease in type 1 and type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608664 · Cited by 1,389
Self-citationRawshani, A., Sattar, N., Franzén, S., Rawshani, A., Hattersley, A. T., Svensson, A.-M., Eliasson, B., & Gudbjörnsdottir, S. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31506-x · Cited by 802
Self-citationReview of statistical methods for analysing healthcare resources and costs
Mihaylova, B., Briggs, A., O'Hagan, A., & Thompson, S. G. (2011) · Health Economics · doi:10.1002/hec.1653 · Cited by 767 · cited 1×
“Data Analysis The univariate analysis of mean values used the t test for differences between the therapy groups on the basis of the central limit theorem, guaranteeing near normality of sample means (11).”
MethodMisso, M. L., Egberts, K. J., Page, M., O'Connor, D., & Shaw, J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005103.pub2 · Cited by 406
Jeitler, K., Horvath, K., Berghold, A., Gratzer, T. W., Neeser, K., Pieber, T. R., & Siebenhofer, A. (2008) · Diabetologia · doi:10.1007/s00125-008-0974-3 · Cited by 375
Khunti, K., Davies, M., Majeed, A., Thorsted, B. L., Wolden, M. L., & Paul, S. K. (2015) · Diabetes Care · doi:10.2337/dc14-0920 · Cited by 356 · cited 1×
“In practice, where individuals with type 1 diabetes face challenges of the disease in daily management, the two modes of insulin administration could differ in effectiveness, ease of use, and association with adverse events and, therefore, be associated with differences in patient outcomes (1,3,4).”
Background(2015) · doi:10.1136/bmj.h3234 · Cited by 258
Self-citationComparison of evidence on harms of medical interventions in randomized and nonrandomized studies
Papanikolaou, P. N. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.050873 · Cited by 229
Roze, S., Smith‐Palmer, J., Valentine, W., de Portu, S., Nørgaard, K., & Pickup, J. C. (2015) · Diabetic Medicine · doi:10.1111/dme.12792 · Cited by 77
Cited by
Grunberger, G., Sherr, J., Allende, M., Blevins, T., Bode, B., Handelsman, Y., Hellman, R., Lajara, R., Roberts, V. L., Rodbard, D., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.04.008 · Cited by 288
Evolution of Insulin Delivery Devices: From Syringes, Pens, and Pumps to DIY Artificial Pancreas
Kesavadev, J., Saboo, B., Krishna, M. B., & Krishnan, G. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00831-z · Cited by 221
Use of Diabetes Technology in Children
Desrochers, H. R., Schultz, A. T., & Laffel, L. M. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.11.001 · Cited by 29
(2021) · doi:10.1007/s00431-020-03883-2 · Cited by 13
Metadata
- Authors
- Toresson Grip, E., Svensson, A.-M., Miftaraj, M., Eliasson, B., Franzén, S., Gudbjörnsdottir, S., & Steen Carlsson, K.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-01-31
- Volume
- 42
- Issue
- 4
- Pages
- 545-552
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2914928335
- Cited by
- 25
- References
- 9
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.